Features

Features

Debates, in-depth articles, and surprising profiles from ASH Clinical News

Pulling Back the Curtain: Steven L. Allen, MD

What was your first job? Technically, my first job as a teenager was in the medical field – I helped install the first window air...

The ACA Out-of-Pocket Limit: Good and Bad News for Hematology Patients

Although the act sets limits on the out-of-pocket expenses a patient might face, many costs associated with hematologic care may fall outside of the...

Stephan Moll, MD: As the Lathe Turns…

What sparked your interest in woodturning? It happened by chance a few years ago: I have always enjoyed building and repairing things, including working with...

Pulling Back the Curtain: Beverly S. Mitchell, MD

  When did you know you wanted to pursue a career in medicine? As early as I can remember, I knew I wanted to be a...

Guy Young, MD: Hematologist, Novelist

Where did the inspiration for Bad Blood come from? One day during my long commute, the idea just popped into my head: what if a...

NOACs: The Novel Kids on the Block

The time has come for clinicians to turn to novel oral anticoagulant agents for the first-line prevention of stroke and systemic embolism in patients with...

Rituximab or Splenectomy in Steroid-Resistant ITP Patients?

Corticosteroids are the standard initial treatment for adult patients with idiopathic thrombocytopenic purpura (ITP), while splenectomy is considered second-line treatment. Drugs like rituximab have...

Grassroots Lobbying Efforts Lead to a Win for SCD Patients in Tennessee: An Interview...

Sickle cell disease (SCD) is the most common, inherited red blood cell disorder in the United States – affecting 70,000 to 100,000 Americans. Although...

Pulling Back the Curtain: Benjamin Ebert, MD, PhD

What was your first job?  In high school, I built up a little business for myself as a math tutor for kids of all ages...

Who Cares About What Patients Think? The FDA, Insurance Payers, Researchers… Maybe You Should...

While patient-reported outcomes (PROs) are nothing new in the field of medicine, they may now be newly appreciated. The U.S. Food and Drug Administration (FDA)...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.